North America Safety Pen Needles Market Worth USD 1.17 billion by 2031, Registering at a CAGR of 6.4% Says Transparency Market Research
11. September 2023 10:19 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global North America safety pen needles market is projected to flourish at a CAGR of...
8.1% CAGR of Human Growth Hormone Market to Reach USD 7.3 Billion by 2032, Says Market.us Research Study
23. Mai 2023 10:03 ET
|
Market.Us
New York, May 23, 2023 (GLOBE NEWSWIRE) -- The Human Growth Hormone Market in terms of revenue was estimated to be worth USD 3.4 Bn in 2022 and is poised to reach USD 7.3 bn by 2032, growing at a...
Growth Hormone Market Size Worth USD 5800 Million by 2030 at 7.60% CAGR – Report by Market Research Future (MRFR)
29. November 2022 09:30 ET
|
Market Research Future
New York, USA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Growth Hormone Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Growth Hormone Market Information By...
Safety Pen Needles Market in North America to Exceed Value of US$ 1.17 Bn by 2031, States TMR Analysis
30. September 2022 09:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The safety pen needles market in North America is prognosticated to surpass a value of US$...
Growth Hormone Market revenue to cross USD 5.3 Bn by 2027: Global Market Insights Inc.
29. April 2021 07:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, April 29, 2021 (GLOBE NEWSWIRE) -- According to latest report “Growth Hormone Market by Product (Powder, Solvent), Application (Growth Hormone Deficiency, Idiopathic Short...
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
07. Januar 2019 09:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...